



(51) **International Patent Classification:**
A61K 31/155 (2006.01) A61P 35/00 (2006.01)
A61K 31/4375 (2006.01)

(21) **International Application Number:**
PCT/US2019/016148

(22) **International Filing Date:**
31 January 2019 (31.01.2019)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
62/624,448 31 January 2018 (31.01.2018) US

(71) **Applicant:** DICIPHERA PHARMACEUTICALS LLC.
[US/US]; 643 Massachusetts St., Suite 200, Lawrence, KS
66044 (US).


(72) **Inventors:** FLYNN, Daniel, L.; 4165 Blackjack Oak Drive,
Lawrence, KS 66047 (US). SMITH, Bryan, D.; 1312
Inverness Drive, Lawrence, KS 66049 (US). GUPTA, Anu;
1212 Chadwick Court, Lawrence, KS 66049 (US).

(74) **Agent:** KAVANAUGH, Theresa, C. et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) **Title:** COMBINATION THERAPY FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMORS



(57) **Abstract:** The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP kinase inhibitor for the treatment of cancers, including c-KIT-mediated cancers, such as GIST.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*